Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "Paradox"
2009
Abstract
The aim was to identify factors that influence the efficacy of 600 mg of clopidogrel pretreatment in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention. In stable coronary artery disease, no correlation exists between baseline PRI and the severity and extent of coronary atherosclerosis.
A high loading dose of clopidogrel does not satisfactorily suppress enhanced PRI in patients with diabetes. Cigarette smoking is independently associated with a prompt antiplatelet response to clopidogrel.
Ongoing statin therapy is an independent determinant of more effective lopidogrel-mediated inhibition of platelet reactivity